Chemotherapy-Free PARP Inhibitor Combination Improves Outcomes versus Single-Agent PARP Inhibitor in Recurrent Ovarian Cancer

Web Exclusives - Ovarian Cancer

The combination of niraparib (Zejula) and bevacizumab (Avastin) as definitive treatment for recurrent platinum-sensitive ovarian cancer was associated with significant improvements in progression-free survival (PFS), time to first subsequent therapy (TFST), second PFS, and time to second subsequent therapy (TSST) in the patients randomized to the niraparib plus bevacizumab combination compared with niraparib alone, reported Mansoor Raza Mirza, MD, Medical Director, Nordic Society of Gynecological Oncology-Clinical Trial Unit, and Chief Oncologist, Rigshospitalet Copenhagen University Hospital, Denmark, and colleagues at the 2020 American Society of Clinical Oncology Virtual Scientific Program.

Furthermore, the chemotherapy-free regimen was well-tolerated and “no detrimental effect on quality of life was observed,” the investigators wrote in their poster presentation.

A total of 97 patients were randomized to niraparib 300 mg once daily plus bevacizumab 15 mg/kg intravenously every 3 weeks until disease progression (N = 48) or single-agent niraparib (N = 49). Treatment was ongoing in 3 patients in each arm; treatment was discontinued due to disease progression in 39 patients in the monotherapy arm and 32 in the combination arm.

PFS, the primary end point of the study, was 12.5 months in the combination arm versus 5.5 months in the single-agent arm (adjusted hazard ratio [HR], 0.34; P <.0001).

TFST was nearly doubled in the combination arm—14.3 months for niraparib plus bevacizumab versus 7.2 months for niraparib alone (adjusted HR, 0.45; P = .0004).

TSST was 21.8 months in the niraparib plus bevacizumab arm versus 17.3 months in the niraparib-alone arm (adjusted HR, 0.56; P = .014).

Overall survival with 52% event maturity was 29.4 months with the niraparib plus bevacizumab combination compared with 27.8 months with single-agent niraparib (adjusted HR, 0.75; P = .30). The study was not powered to detect a difference in overall survival, nor any of the other efficacy end points, the investigators noted.

The change in mean global health status/quality of life over time as measured by the European Organisation for Research and Treatment of Cancer QLQ-C30 scale was not different between the 2 treatment arms at 10 months postrandomization.

Hypertension and proteinuria were more common in the combination arm compared with the monotherapy arm. The rate of grade 3/4 hypertension was 22.9% versus 0%, respectively.

“These results support the rationale behind a randomized phase 3 trial to change current standard-of-care therapy,” the investigators concluded.

Related Items
ASCO Guidelines Support PARP Inhibitor Use in Maintenance and Recurrent Setting of Advanced Ovarian Cancer
Web Exclusives published on October 13, 2020 in Ovarian Cancer
Niraparib Efficacy in Advanced Ovarian Cancer Extends to All Biomarker Subgroups
Web Exclusives published on October 13, 2020 in Ovarian Cancer
Olaparib/Bevacizumab as First-Line Maintenance Reduces Risk for Progression or Death in Patients with Advanced Ovarian Cancer
Web Exclusives published on October 13, 2020 in Ovarian Cancer
Online Delivery of Genetic Services: No Increase in Cancer Risk Distress versus Telephone Counseling
Web Exclusives published on October 13, 2020 in Ovarian Cancer
Phase 2 OVARIO Update: Promising Survival Rates in Patients with Advanced Ovarian Cancer Treated with Niraparib plus Bevacizumab Maintenance
Web Exclusives published on September 15, 2020 in Ovarian Cancer
No Difference in PFS Between Platinum-Based Chemotherapy and Olaparib in Women with Platinum-Sensitive Ovarian Cancer
Web Exclusives published on September 15, 2020 in Ovarian Cancer
PARP Inhibitors Do Not Significantly Increase Risk for Secondary Hematologic Malignancy
Web Exclusives published on September 15, 2020 in Ovarian Cancer
Safety of Approved Rucaparib Starting Dose Confirmed from Pooled Analysis
Web Exclusives published on September 15, 2020 in Ovarian Cancer
Phase 3 Study to Investigate Anti–PD-1 Antibody in the Treatment of High-Grade Ovarian Cancer
Web Exclusives published on September 15, 2020 in Ovarian Cancer
Olaparib Extends Survival by >1 Year in Women with Relapsed Ovarian Cancer and BRCA Mutation
Web Exclusives published on July 28, 2020 in Ovarian Cancer
Last modified: July 28, 2020